All blog articles
Dexcom CGM Explained

Dexcom G7 now integrates with Omnipod® 5


Jan. 22, 20255 min read

The content in this article should not be taken as medical advice. Please consult your healthcare provider regarding your individual health needs. 
Dexcom G7 and Omnipod 5 is the 1st and only waterproof AID system for people with type 1 or type 2 diabetes†-§—learn how the two are a great team!
The Dexcom G7 Continuous Glucose Monitoring (CGM) System and Omnipod 5 are in continuous communication, giving you the ability to see your glucose data in real time from the included Controller, compatible smartphone,* or smart watch.*





*Smart device sold separately. For a list of compatible devices, visit www.Dexcom.com/compatibility. †The Dexcom G7 sensor is waterproof and may be submerged under eight feet of water. ‡The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Personal Diabetes Manager and Controller are not waterproof. §More time in automated mode based on 30 min warm up time for Dexcom G7 versus 2 hours with Dexcom G6. During sensor warm up the system enters Automated Mode: Limited. ||Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. ¶Internet connection and separate Follow app required. To view compatibility, visit www.dexcom.com/compatibility.
1 Dexcom, data on file, 2023. 2 Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. 3-mo Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et al. Diabetes Care (2021). 3 Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose (>180mg/dL) from CGM in standard therapy vs Omnipod 5 = 39.4% vs. 29.5%. Average time with low blood glucose (<70mg/dL) from CGM in standard therapy vs Omnipod 5 = 3.41% vs. 2.13%. Sherr JL, et al. Diabetes Care (2022).
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. 

Related articles

View all
Privacy PolicyTerms of Use

MAT-5161

MAT-5003

© Dexcom, Inc. All rights reserved.

US flag

US